Press Releases - IGC Pharma, INC.

Press Releases

IGC-Pharma-Introduces-MINT-AD

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer’s Risk and Accelerate Early Detection

IGC-Reports-Financial-Results-for-Fiscal-Year-Ended-March-31,-2025

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights – A Year of Transformative Progress in Alzheimer’s Innovation

IGC-Pharma-Host-Fiscal-Year-June-25-2025 (1)

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on June 30, 2025

IGC-Pharma-Expands-CALMA-Trial-to-Oklahoma

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

IGC-Pharma-Calma-Phase2-Alzheimer’s-Market

IGC Pharma’s Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer’s Market

IGC-Pharma-Alzheimers-Melatonin-Toxicity-Safety

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

IGC-Pharma-Alzheimers-Innovation-AI-Advisory (2)

IGC Pharma Welcomes Strategic Investment from Advisors

IGC-Pharma-Alzheimers-Innovation-AI-Advisory

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer’s Innovation and AI-Driven Programs

IGC-Pharma-Alzheimers-Butler-Hospital-Aging

IGC Pharma Expands CALMA Alzheimer’s Phase 2 Trial with Prestigious Research Site at Butler Hospital’s Memory and Aging Program

IGC-Pharma-Alzheimers-Miami-Jewish-Trial

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

IGC-Pharma-Alzheimers-Reduction-Sleep-Disturbances

IGC Pharma’s Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

IGC-Pharma-Alzheimers-Hamilton-Health-Trial

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

IGC-Pharma-Alzheimers-BayCare-Health-Trial-Florida

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

IGC-Pharma-Alzheimers-Equity-Analyst-Coverage-AGP (1)

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25”

IGC-Pharma-Alzheimers-Equity-Analyst-Coverage-AGP

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”

IGC-Pharma-Alzheimers-AI-Dementia-Diagnostic

IGC Pharma Expands AI Platform with Advanced Diagnostic Model for Alzheimer’s and Dementia Detection